| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Sitaxentan sodium (formerly IPI-1040; TBC-11251; IPI 1040; TBC11251; Thelin), the sodium salt of Sitaxentan, is a selective and orally bioavailable endothelin A receptor (ETA) antagonist with anti-hypertensive activity. It suppresses ETA with IC50 and Ki of 1.4 nM and 0.43 nM, respectively. For the treatment of pulmonary arterial hypertension (PAH), sitaxentani is an authorized drug.
| ln Vitro |
|
|
|---|---|---|
| ln Vivo |
|
|
| Enzyme Assay |
Binding studies are conducted using 2 mg/tube (ETA) or 0.75 mg/tube (ETB) membrane in a 30 mM HEPES buffer, pH 7.4, with 150 mM NaCl, 5 mM MgCl2, and 0.05% bacitracin. A final concentration of 0.25% DMSO is obtained by dissolving sitaxentan sodium in DMSO and diluting it with the assay buffer. In a final volume of 200 μL containing 4 pM [125I]ET-1 (1.6 nCi), competitive inhibition experiments are carried out in triplicate. In the presence of 100 nM ET-1, nonspecific binding is found. Samples are incubated for 16 hours−18 hours at 24 °C. After adding one milliliter of PBS, the experiment is centrifuged at 2000 g for 25 minutes at 4 °C. On a Genesys gamma counter, the membrane-bound radioactivity is counted after the supernatant has been decanted.
|
|
| Cell Assay |
Transfected COS or TE 671 In six-well plates, seven cells are grown to confluence. Two milliliters of inositol-free RPMI-164 (IF-RPMI) media, containing two milliliters of [3H]myoinositol and ten percent inositol-free FCS, are added to each well's media sixteen hours before use. The wells are then incubated at 37 °C with 6% CO2. The cells undergo two PBS washes after the medium is aspirated. One milliliter of lithium buffer (15 μM HEPES, pH 7.4, 145 μM NaCl, 5.4 μM KCl, 1.8 μM CaCl2, 0.8 μM MgSO4, 1.0 μM NaH2PO4, 11.2 μM glucose, 20 μM LiCl) with or without sitaxentan sodium is used to preincubate cells for ten minutes before adding 100 μM of ET-1 at various concentrations. After that, the cells are incubated for a further forty-five minutes. The accumulated inositol phosphates are extracted using ice-cold methanol after the buffer is thrown away. After solubilizing the cells in 0.1 M NaOH, the total protein content of each well is determined using the BCA assay.
|
|
| Animal Protocol |
|
|
| References |
|
|
| Additional Infomation |
Drug Indication
Treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease. |
| Molecular Formula |
C18H14CLN2NAO6S2
|
|
|---|---|---|
| Molecular Weight |
476.89
|
|
| Exact Mass |
475.988
|
|
| Elemental Analysis |
C, 45.34; H, 2.96; Cl, 7.43; N, 5.87; Na, 4.82; O, 20.13; S, 13.45
|
|
| CAS # |
210421-74-2
|
|
| Related CAS # |
Sitaxsentan; 184036-34-8
|
|
| PubChem CID |
11477084
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| LogP |
4.9
|
|
| Hydrogen Bond Donor Count |
0
|
|
| Hydrogen Bond Acceptor Count |
9
|
|
| Rotatable Bond Count |
6
|
|
| Heavy Atom Count |
30
|
|
| Complexity |
726
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
ClC1C(C([H])([H])[H])=NOC=1[N-]S(C1C([H])=C([H])SC=1C(C([H])([H])C1=C([H])C2=C(C([H])=C1C([H])([H])[H])OC([H])([H])O2)=O)(=O)=O.[Na+]
|
|
| InChi Key |
MDTNUYUCUYPIHE-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C18H14ClN2O6S2.Na/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18;/h3-5,7H,6,8H2,1-2H3;/q-1;+1
|
|
| Chemical Name |
sodium;(4-chloro-3-methyl-1,2-oxazol-5-yl)-[2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophen-3-yl]sulfonylazanide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 33.33 mg/mL (69.89 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0969 mL | 10.4846 mL | 20.9692 mL | |
| 5 mM | 0.4194 mL | 2.0969 mL | 4.1938 mL | |
| 10 mM | 0.2097 mL | 1.0485 mL | 2.0969 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00810732 | Completed | Drug: Open Drug: Nifedipine Drug: Placebo |
Chronic Kidney Disease | Pfizer | May 9, 2007 | Phase 2 |
| NCT00744211 | Completed | Other: Vehicle Drug: 1mg/kg sitaxsentan sodium |
Heart Disease | VA Office of Research and Development |
July 2008 | Not Applicable |
| NCT00303498 | Completed | Drug: Sitexsentin sodium Drug: Placebo |
Diastolic Heart Failure | Pfizer | June 2007 | Phase 2 |
| NCT00080457 | Completed | Drug: sitaxsentan sodium | Pulmonary Hypertension | Encysive Pharmaceuticals | May 2003 | Phase 3 |
| NCT01445873 | Completed | Drug: Sitaxentan sodium/ Placebo |
Healthy | Pfizer | September 2009 | Phase 1 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
